朱迪 · 赞德博士现任美国食品药品管理局（FDA）药品评价与研究中心（CDER）监测与流行病办公室（OSE）的药物警戒与流行病学部（OPE）主任。她负责药物警戒一处和二处。这两个处室负责开展药品安全流行病工作和药物警戒项目。
Judy Zander is the Director of the Office of Pharmacovigilance and Epidemiology (OPE), in the Office of Surveillance and Epidemiology (OSE), in the Center for Drug Evaluation (CDER) at the U.S. Food and Drug Administration (FDA). In this capacity, she oversees the Divisions of Pharmacovigilance 1 and 2, the Divisions of Epidemiology 1 and 2, including drug safety epidemiology activities and pharmacovigilance programs.
Judy joined FDA in January 2017. She has more than 20 years of pharmaceutical industry experience in drug safety, and risk management. She has experience with branded and generic products, from clinical development through post market use, in all therapeutic areas.
Prior to joining FDA, Judy was the Vice President of medical scientific strategy in Global Pharmacovigilance.
Judy held prior positions with increasing responsibility at AstraZeneca, Novartis, and Johnson and Johnson. She has supported and lead internal and external pharmacovigilance activities, including being a member of the CIOMS IX Expert working group regarding the application of Risk Management Tools.
Judy is a licensed and board certified internist. She earned her medical degree from New York Medical College and a bachelor’s degree in chemistry from Brooklyn College.
In her free time, Judy enjoys biking and spending time with her family.